The critical role of the class III histone deacetylase SIRT2 in stabilizing N-Myc oncoprotein. Cancer is the commonest cause of death from disease in children. Neuroblastoma is the commonest solid tumor in early childhood. This project will investigate the critical roles of SIRT2 protein in increasing the expression of N-Myc oncoprotein and consequently inducing neuroblastoma, and SIRT2 inhibitors as anticancer agents.
Mitochondrially targeted anti-cancer drugs modulate the mitochondrial genome. Successful cancer management requires novel therapeutical approaches. This project will test the effect of a new class of compounds that target mitochondria, the powerhouse of the cells, where they suppress expression of mitochondrial genes. By this mechanism, cancers that are resistant to apoptosis induction can be inhibited.
Ketamine Therapy Among Patients With Treatment-resistant Depression: A Randomised, Double-blind, Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,069,382.00
Summary
In the last decade, there have been reports of powerful antidepressant effects after a single injection of anaesthetic ketamine, with dramatic (though shortlasting) effects within 24 hours. This will be the first controlled study to test whether a course of repeated ketamine treatments, given over 4 weeks, is effective and safe in treating depression.
Targeting PI3K-regulated Small Non-coding RNAs To Restore Cardiac Function
Funder
National Health and Medical Research Council
Funding Amount
$610,204.00
Summary
Heart failure affects approximately 2.4% of the adult population and over 11% of people over 80 years old. The majority of existing therapies slow, rather than reverse heart failure progression. The primary goal of this study is to determine whether regulating novel regulatory genes can enhance cardiac function in a setting of heart failure. Ultimately, technologies that target these genes may lead to innovative pharmacotherapies in the clinical management of heart failure.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100082
Funder
Australian Research Council
Funding Amount
$180,000.00
Summary
FACSAria III - Fluorescence activated cell sorter. Flow cytometry is a technique for counting and examining microscopic particles, such as cells and chromosomes, by suspending them in a stream of fluid and passing them by an electronic detection apparatus. The FACSAria III cell sorter will be used to establish a core facility for sorting cells. The outcomes from using this technology are a better understanding cellular and genetic understanding of cancer, respiratory diseases, reproduction and ....FACSAria III - Fluorescence activated cell sorter. Flow cytometry is a technique for counting and examining microscopic particles, such as cells and chromosomes, by suspending them in a stream of fluid and passing them by an electronic detection apparatus. The FACSAria III cell sorter will be used to establish a core facility for sorting cells. The outcomes from using this technology are a better understanding cellular and genetic understanding of cancer, respiratory diseases, reproduction and birth. Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE190100668
Funder
Australian Research Council
Funding Amount
$422,574.00
Summary
Cysteamine dioxygenases: novel oxygen sensors implicated in hypoxia? This project aims to characterise and manipulate a novel oxygen sensing system, the cysteamine dioxygenases, to help understand how mammalian cells respond to low oxygen concentrations, a condition known as hypoxia. A number of the world’s most destructive diseases can impair oxygen delivery, altering biochemical landscapes. By understanding how cells respond to fluctuations in oxygen, the project expects to develop effective m ....Cysteamine dioxygenases: novel oxygen sensors implicated in hypoxia? This project aims to characterise and manipulate a novel oxygen sensing system, the cysteamine dioxygenases, to help understand how mammalian cells respond to low oxygen concentrations, a condition known as hypoxia. A number of the world’s most destructive diseases can impair oxygen delivery, altering biochemical landscapes. By understanding how cells respond to fluctuations in oxygen, the project expects to develop effective methods to treat these detrimental conditions. Characterisation of the cysteamine dioxygenases could establish a novel mechanism by which cells monitor changes in oxygen, assisting in understanding hypoxia and disease. The project will also enable new cysteine initiating substrates to be identified, allowing the full impact of this regulatory process to be appreciated in mammals.Read moreRead less
Understanding endocrine tumorigenesis - opportunities for new diagnostics and therapies. This project will generate new knowledge significant for improving cancer diagnosis and designing new therapies for cancer patients as we embrace the personalised medicine era. Specific focus is on endocrine tumours. This research has as its aim improved survival for people diagnosed with cancer.
Targeting Drug-Resistance In Paediatric Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$649,048.00
Summary
Leukaemia is the most common type of cancer in children but resistance to therapy continues to be a significant problem. This project will investigate the biology of drug-resistance and relapse using a mouse model that replicates the human disease. We hope to identify novel therapeutic targets that can be used in combination with existing therapies to improve outcomes in this disease, particularly for patients that develop drug-resistance such as those at the time of relapse.
Mammalian chitinases and gene therapy: new weapons to combat fungal and insect attack in mammals. Plants combat fungal and insect attack by producing chitin degrading enzymes. Related, chitinolytic enzymes have been identified in mammals, but their functions are unclear. We found that chitinases from human macrophages inhibited fungal growth. We hypothesise that, like plants, mammalian chitinases are produced to fight chitin containing pathogens. We will transform cells with a chitotriosidase ge ....Mammalian chitinases and gene therapy: new weapons to combat fungal and insect attack in mammals. Plants combat fungal and insect attack by producing chitin degrading enzymes. Related, chitinolytic enzymes have been identified in mammals, but their functions are unclear. We found that chitinases from human macrophages inhibited fungal growth. We hypothesise that, like plants, mammalian chitinases are produced to fight chitin containing pathogens. We will transform cells with a chitotriosidase gene and encapsulate them, creating bioreactors secreting chitinases. Therapeutic effects will be tested by grafting bioreactors to mice inoculated with Aspergillus. The research is a new approach to fighting chitin containing pathogens, with potential applications from parasite infestations in livestock to fungal infections in humans.Read moreRead less